To get on it, a substance generally has to clear three hurdles: it can't be a component of an FDA-approved drug, it can't have an applicable USP/NF monograph, and it has to satisfy the criteria FDA weighs when adding new entries clinical need, safety, and quality controls
These findings highlight the potential of Phlomis tuberosa as a natural source for developing adjunct therapies targeting glaucoma, leveraging its enzyme-inhibitory and antioxidant properties [149]
Within the late-stage pipeline assets (around half of which are targeting weight management), eight are oral ones, aiming to solve the inconvenience of injections, and approximately 20 are dual-target or triple-target, aiming to achieve superiority in clinical effectiveness
The treatment starts with a big dose, then smaller doses are given regularly